RhuDex Clinical Development to Continue Following Feedback from
Regulatory Authorities

(Thomson Reuters ONE) - Lund, Sweden, October 5, 2009 - Active Biotech AB's (NASDAQ OMXNordic: ACTI) collaboration partner MediGene AG (Frankfurt: MDG,Prime Standard, TecDAX) today announce information regarding thecandidate drug RhuDex(TM) for the treatment of rheumatoid arthritis.MediGene AG has received feedback from the UK MHRA (Medicines andHealthcare products Regulatory Agency) regarding the in-vitro studiesconducted with RhuDex. Since these tests did not suggest any negativeeffects of RhuDex, the MHRA agreed to a continuation of the drugcandidate's clinical development.To read the complete press release, please see www.medigene.com.Lund, October 5, 2009Active Biotech AB (publ)Tomas LeandersonPresident and CEOFor further information, please contact:Göran Forsberg, VP Investor Relations & Business DevelopmentTel: +46 (0) 46 19 11 54E-mail: goran.forsberg(at)activebiotech.comNotes to editorsAbout RhuDex(TM)RhuDex(TM) is a novel, orally available compound for the treatment ofrheumatoid arthritis, originating from Active Biotech's patented CD80antagonists, out-licensed to MediGene AG. RhuDex(TM) is beingdeveloped as a disease-modifying drug for the treatment of rheumaticdiseases.About Active BiotechActive Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnologycompany with focus on autoimmune/inflammatory diseases and cancer.Projects in pivotal phase are laquinimod, an orally administeredsmall molecule with unique immunomodulatory properties for thetreatment of multiple sclerosis, as well as ANYARA for use in cancertargeted therapy, primarily of renal cancer. Further key projects inclinical development comprise the three orally administered compoundsTASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Pleasevisit www.activebiotech.com for more information.Active Biotech ABPO Box 724, SE-220 07 LundSwedenTel: +46 (0)46-19 20 00Fax: +46 (0)46-19 11 00Active Biotech is required under the Securities Markets Act to makethe information in this press release public. The information wassubmitted for publication at 11:30 a.m. CET on October 5, 2009.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 05.10.2009 - 11:30 Uhr
Sprache: Deutsch
News-ID 6565
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 417 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"RhuDex Clinical Development to Continue Following Feedback from
Regulatory Authorities"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech